866-997-4948(US-Canada Toll Free)

Colorectal Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Jun 2016

Category :

Cancer

No. of Pages : 1564 Pages

Colorectal Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Colorectal Cancer - Pipeline Review, H1 2016, provides an overview of the Colorectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer
- The report reviews pipeline therapeutics for Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Colorectal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Colorectal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 8
Colorectal Cancer Overview 9
Therapeutics Development 10
Colorectal Cancer - Therapeutics under Development by Companies 12
Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 32
Colorectal Cancer - Pipeline Products Glance 34
Colorectal Cancer - Products under Development by Companies 38
Colorectal Cancer - Products under Investigation by Universities/Institutes 65
Colorectal Cancer - Companies Involved in Therapeutics Development 68
Colorectal Cancer - Therapeutics Assessment 295
Drug Profiles 339
Colorectal Cancer - Dormant Projects 1462
Colorectal Cancer - Discontinued Products 1489
Colorectal Cancer - Product Development Milestones 1496
Appendix 1513

List of Tables
Number of Products under Development for Colorectal Cancer, H1 2016 60
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H1 2016 61
Number of Products under Development by Companies, H1 2016 63
Number of Products under Development by Companies, H1 2016 (Contd..1) 64
Number of Products under Development by Companies, H1 2016 (Contd..2) 65
Number of Products under Development by Companies, H1 2016 (Contd..3) 66
Number of Products under Development by Companies, H1 2016 (Contd..4) 67
Number of Products under Development by Companies, H1 2016 (Contd..5) 68
Number of Products under Development by Companies, H1 2016 (Contd..6) 69
Number of Products under Development by Companies, H1 2016 (Contd..7) 70
Number of Products under Development by Companies, H1 2016 (Contd..8) 71
Number of Products under Development by Companies, H1 2016 (Contd..9) 72
Number of Products under Development by Companies, H1 2016 (Contd..10) 73
Number of Products under Development by Companies, H1 2016 (Contd..11) 74
Number of Products under Development by Companies, H1 2016 (Contd..12) 75
Number of Products under Development by Companies, H1 2016 (Contd..13) 76
Number of Products under Development by Companies, H1 2016 (Contd..14) 77
Number of Products under Development by Companies, H1 2016 (Contd..15) 78
Number of Products under Development by Companies, H1 2016 (Contd..16) 79
Number of Products under Development by Companies, H1 2016 (Contd..17) 80
Number of Products under Development by Companies, H1 2016 (Contd..18) 81
Number of Products under Investigation by Universities/Institutes, H1 2016 82
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 83
Comparative Analysis by Late Stage Development, H1 2016 84
Comparative Analysis by Clinical Stage Development, H1 2016 85
Comparative Analysis by Early Stage Development, H1 2016 86
Comparative Analysis by Unknown Stage Development, H1 2016 87
Products under Development by Companies, H1 2016 88
Products under Development by Companies, H1 2016 (Contd..1) 89
Products under Development by Companies, H1 2016 (Contd..2) 90
Products under Development by Companies, H1 2016 (Contd..3) 91
Products under Development by Companies, H1 2016 (Contd..4) 92
Products under Development by Companies, H1 2016 (Contd..5) 93
Products under Development by Companies, H1 2016 (Contd..6) 94
Products under Development by Companies, H1 2016 (Contd..7) 95
Products under Development by Companies, H1 2016 (Contd..8) 96
Products under Development by Companies, H1 2016 (Contd..9) 97
Products under Development by Companies, H1 2016 (Contd..10) 98
Products under Development by Companies, H1 2016 (Contd..11) 99
Products under Development by Companies, H1 2016 (Contd..12) 100
Products under Development by Companies, H1 2016 (Contd..13) 101
Products under Development by Companies, H1 2016 (Contd..14) 102
Products under Development by Companies, H1 2016 (Contd..15) 103
Products under Development by Companies, H1 2016 (Contd..16) 104
Products under Development by Companies, H1 2016 (Contd..17) 105
Products under Development by Companies, H1 2016 (Contd..18) 106
Products under Development by Companies, H1 2016 (Contd..19) 107
Products under Development by Companies, H1 2016 (Contd..20) 108
Products under Development by Companies, H1 2016 (Contd..21) 109
Products under Development by Companies, H1 2016 (Contd..22) 110
Products under Development by Companies, H1 2016 (Contd..23) 111
Products under Development by Companies, H1 2016 (Contd..24) 112
Products under Development by Companies, H1 2016 (Contd..25) 113
Products under Development by Companies, H1 2016 (Contd..26) 114
Products under Investigation by Universities/Institutes, H1 2016 115
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 116
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 117
Colorectal Cancer - Pipeline by 2cureX ApS, H1 2016 118
Colorectal Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016 119
Colorectal Cancer - Pipeline by 4SC AG, H1 2016 120
Colorectal Cancer - Pipeline by AB Science SA, H1 2016 121
Colorectal Cancer - Pipeline by AbbVie Inc., H1 2016 122
Colorectal Cancer - Pipeline by AbGenomics International, Inc., H1 2016 123
Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 124
Colorectal Cancer - Pipeline by Adamed Sp. z o.o., H1 2016 125
Colorectal Cancer - Pipeline by Advaxis, Inc., H1 2016 126
Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 127
Colorectal Cancer - Pipeline by Alchemia Limited, H1 2016 128
Colorectal Cancer - Pipeline by Allinky Biopharma, H1 2016 129
Colorectal Cancer - Pipeline by Amal Therapeutics SA, H1 2016 130
Colorectal Cancer - Pipeline by Amgen Inc., H1 2016 131
Colorectal Cancer - Pipeline by Antibe Therapeutics, Inc., H1 2016 132
Colorectal Cancer - Pipeline by Apac Biotech Pvt Ltd, H1 2016 133
Colorectal Cancer - Pipeline by Apexigen, Inc., H1 2016 134
Colorectal Cancer - Pipeline by Aphios Corporation, H1 2016 135
Colorectal Cancer - Pipeline by Aposense Ltd., H1 2016 136
Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 137
Colorectal Cancer - Pipeline by ArQule, Inc., H1 2016 138
Colorectal Cancer - Pipeline by Array BioPharma Inc., H1 2016 139
Colorectal Cancer - Pipeline by Astellas Pharma Inc., H1 2016 140
Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 141
Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2016 142
Colorectal Cancer - Pipeline by ATLAB Pharma SAS, H1 2016 143
Colorectal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 144
Colorectal Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016 145
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2016 146
Colorectal Cancer - Pipeline by Bayer AG, H1 2016 147
Colorectal Cancer - Pipeline by BeiGene, Ltd., H1 2016 148
Colorectal Cancer - Pipeline by Biocon Limited, H1 2016 149
Colorectal Cancer - Pipeline by Bionomics Limited, H1 2016 150
Colorectal Cancer - Pipeline by Bionovis SA, H1 2016 151
Colorectal Cancer - Pipeline by Biotecnol, Inc., H1 2016 152
Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 153
Colorectal Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 154
Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 155
Colorectal Cancer - Pipeline by Burzynski Research Institute, Inc., H1 2016 156
Colorectal Cancer - Pipeline by Calithera Biosciences, Inc., H1 2016 157
Colorectal Cancer - Pipeline by Carna Biosciences, Inc., H1 2016 158
Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H1 2016 159
Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2016 160
Colorectal Cancer - Pipeline by Celator Pharmaceuticals, Inc., H1 2016 161
Colorectal Cancer - Pipeline by Celgene Corporation, H1 2016 162
Colorectal Cancer - Pipeline by Cellceutix Corporation, H1 2016 163
Colorectal Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 164
Colorectal Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016 165
Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2016 166
Colorectal Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016 167
Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016 168
Colorectal Cancer - Pipeline by Cipla Ltd., H1 2016 169
Colorectal Cancer - Pipeline by Cleave Biosciences, H1 2016 170
Colorectal Cancer - Pipeline by Cleveland BioLabs, Inc., H1 2016 171
Colorectal Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016 172
Colorectal Cancer - Pipeline by Coare Biotechnology, Inc., H1 2016 173
Colorectal Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016 174
Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 175
Colorectal Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016 176
Colorectal Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 177
Colorectal Cancer - Pipeline by CritiTech, Inc., H1 2016 178
Colorectal Cancer - Pipeline by CrystalGenomics, Inc., H1 2016 179
Colorectal Cancer - Pipeline by Cytune Pharma SAS, H1 2016 180
Colorectal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 181
Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2016 182
Colorectal Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 183
Colorectal Cancer - Pipeline by Delcath Systems, Inc., H1 2016 184
Colorectal Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 185
Colorectal Cancer - Pipeline by Digna Biotech, S.L., H1 2016 186
Colorectal Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016 187
Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 188
Colorectal Cancer - Pipeline by EirGenix Inc., H1 2016 189
Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2016 190

List of Figures
Number of Products under Development for Colorectal Cancer, H1 2016 60
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H1 2016 61
Number of Products under Development by Companies, H1 2016 62
Number of Products under Investigation by Universities/Institutes, H1 2016 82
Comparative Analysis by Late Stage Development, H1 2016 84
Comparative Analysis by Clinical Stage Development, H1 2016 85
Comparative Analysis by Early Stage Products, H1 2016 86
Assessment by Monotherapy Products, H1 2016 345
Assessment by Combination Products, H1 2016 346
Number of Products by Top 10 Targets, H1 2016 347
Number of Products by Stage and Top 10 Targets, H1 2016 347
Number of Products by Top 10 Mechanism of Actions, H1 2016 366
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 366
Number of Products by Top 10 Routes of Administration, H1 2016 385
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 385
Number of Products by Top 10 Molecule Types, H1 2016 387
Number of Products by Stage and Top 10 Molecule Types, H1 2016 387

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *